SEC Form 4 · accession 0001493152-26-039495

INTERPACE BIOSCIENCES, INC. · IDXG

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — CFO & COO

Period of report

Aug 20, 2026

Accepted (ET)

Aug 20, 2026 · 4:59 pm EDT

Rule 10b5-1 plan

box not checked

Issuer CIK

0001054102

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Aug 20, 2026	M	277,009	$0.00	A	323,800	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Restricted Stock Units^F2,F3	—	Aug 20, 2026	A	554,018	A	—	—	Common Stock	554,018	554,018	D
Restricted Stock Units^F2,F3	—	Aug 20, 2026	M	277,009	D	—	—	Common Stock	277,009	277,009	D
Stock Option (right to buy)^F4	$2.02	Aug 20, 2026	A	277,009	A	—	Aug 20, 2036	Common Stock	277,009	277,009	D

F1Represents the conversion upon vesting of restricted stock units (RSUs) into shares of common stock of Interpace Biosciences, Inc. On August 20, 2026, the Reporting Person was granted 554,018 RSUs, of which 277,009 vested upon grant and 277,009 will vest on August 20, 2027, subject to the Reporting Person's continued service on such vesting date.
F2Each RSU represents a contingent right to receive the economic equivalent of one share of common stock of Interpace Biosciences, Inc.
F3On August 20, 2026, the Reporting Person was granted 554,018 RSUs, of which 277,009 vested upon grant and 277,009 will vest on August 20, 2027, subject to the Reporting Person's continued service on such vesting date.
F4The options will vest in four equal annual installments beginning on August 20, 2027, subject to the Reporting Person's continued service on each such vesting date.